MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 597-605

  Hershkovitz Rokah, Oshrat ^a   Modai, Shira ^a   Pasmanik Chor, Metsada ^a   Toren, Amos ^b   Shomron, Noam ^a   Raanani, Pia ^a   Shpilberg, Ofer ^c   Granot, Galit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Safra Children's Hospital   (Israel)

^c ASSUTA MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; BCR ABL; CML; Imatinib; MiR 30e

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MICRORNA; MICRORNA 30E; MICRORNA 30E INHIBITOR; MICRORNA 30E MIMIC; RNA DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; MESSENGER RNA; MIRN30 MICRORNA, HUMAN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIZATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; K562 CELL LINE; LEUKEMIA CELL; LUCIFERASE ASSAY; UPREGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICRORNAS; PIPERAZINES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84919460649     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.006     Document Type: Article

References (33)

1. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
2. Savage D.G., Antman K.H. Imatinib mesylate-a new oral targeted therapy. N. Engl. J. Med 2002, 346:683-693.
3. Spizzo R., Nicoloso M.S., Croce C.M., Calin G.A. SnapShot: MicroRNAs in Cancer. Cell 2009, 137:586. e581.
4. Ramkissoon S.H., Mainwaring L.A., Ogasawara Y., Keyvanfar K., McCoy J.P., Sloand E.M., et al. Hematopoietic-specific microRNA expression in human cells. Leuk. Res 2006, 30:643-647.
5. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
6. O'Day E., Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010, 12:201.
7. Nana-Sinkam S.P., Geraci M.W. MicroRNA in lung cancer. J. Thorac. Oncol 2006, 1:929-931.
8. Li S., Fu H., Wang Y., Tie Y., Xing R., Zhu J., et al. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2009, 49:1194-1202.
9. Xu C., Liu S., Fu H., Li S., Tie Y., Zhu J., et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur. J. Cancer 2010, 46:2828-2836.
10. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033.
11. Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 2006, 5:29.
12. Garzon R., Pichiorri F., Palumbo T., Visentini M., Aqeilan R., Cimmino A., et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007, 26:4148-4157.
13. Zanette D.L., Rivadavia F., Molfetta G.A., Barbuzano F.G., Proto-Siqueira R., Silva W.A., et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res 2007, 40:1435-1440.
14. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med 2005, 353:1793-1801.
15. Li Y., Wang H., Tao K., Xiao Q., Huang Z., Zhong L., et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp. Cell Res 2013, 319:1094-1101.
16. Xu C., Fu H., Gao L., Wang L., Wang W., Li J., et al. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Oncogene 2014, 33:44-54.
17. Agirre X., Jimenez-Velasco A., San Jose-Eneriz E., Garate L., Bandres E., Cordeu L., et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol. Cancer Res 2008, 6:1830-1840.
18. Suresh S., McCallum L., Lu W., Lazar N., Perbal B., Irvine A.E. MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. J. Cell Commun. Signal 2011, 5:183-191.
19. Liu Y., Song Y., Ma W., Zheng W., Yin H. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia. Leuk. Res 2013, 37:349-356.
20. Rokah O.H., Granot G., Ovcharenko A., Modai S., Pasmanik-Chor M., Toren A., et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS ONE 2012, 7. e35501.
21. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
22. Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
23. Johnson-Ansah H., Guilhot J., Rousselot P., Rea D., Legros L., Rigal-Huguet F., et al. Tolerability and efficacy of pegylated interferon-alpha-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. Cancer 2013, 119:4284-4289.
24. Breccia M., Alimena G. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. Leuk. Res 2013, 37:713-720.
25. Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Branford S., Kim D.W., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol 2010, 28:424-430.
26. Breccia M., Alimena G. How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages. Cancer Lett 2012, 322:127-132.
27. Gafter-Gvili A., Leader A., Gurion R., Vidal L., Ram R., Shacham-Abulafia A., et al. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients - systematic review and meta-analysis. Am. J. Hematol 2011, 86:657-662.
28. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
29. Wang V., Wu W. MicroRNA-based therapeutics for cancer. Biodrugs 2009, 23:15-23.
30. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
31. Venturini L., Battmer K., Castoldi M., Schultheis B., Hochhaus A., Muckenthaler M.U., et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007, 109:4399-4405.
32. Stallings R.L., Nair P., Maris J.M., Catchpoole D., McDermott M., O'Meara A., et al. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 2006, 66:3673-3680.
33. Yu F., Deng H., Yao H., Liu Q., Su F., Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010, 29:4194-4204.